Search

Your search keyword '"Khan, Muhammad Shahzeb"' showing total 111 results

Search Constraints

Start Over You searched for: Author "Khan, Muhammad Shahzeb" Remove constraint Author: "Khan, Muhammad Shahzeb" Publisher wiley-blackwell Remove constraint Publisher: wiley-blackwell
111 results on '"Khan, Muhammad Shahzeb"'

Search Results

2. Role of anti‐obesity drugs in heart failure regardless of ejection fraction.

3. Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial and comparison to COAPT and MITRA‐FR trials

4. Role of telemedicine in the management of obesity: State‐of‐the‐art review.

5. Guideline‐directed medical therapy for heart failure: The key ingredient for successful in‐hospital and post‐discharge care.

6. Why do clinicians not prescribe quadruple medical therapy for heart failure with reduced ejection fraction?

7. The effect of sodium–glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta‐analysis.

8. Accelerometer vs. other activity measures in heart failure with preserved ejection fraction: the VITALITY‐HFpEF trial.

9. Association of diabetes‐specific heart failure risk score with presence of subclinical cardiomyopathy among individuals with diabetes: A prospective study.

11. Artificial intelligence and heart failure: A state‐of‐the‐art review.

12. Kidney involvement in transthyretin cardiac amyloidosis – Role of urinary albumin to creatinine ratio and need for further evidence generation.

13. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta‐analysis.

15. Pressures do not equal volumes: implications for heart failure management in patients with CardioMEMS.

16. Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced.

18. Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trial.

24. Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.

25. Defining changes in physical limitation from the patient perspective: insights from the VITALITY‐HFpEF randomized trial.

26. Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.

27. Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018.

28. Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure.

29. Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia.

30. Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of 'too little, too late'.

31. Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map.

32. Sodium–glucose co‐transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism.

34. Uninterrupted versus interrupted direct oral anticoagulation for catheter ablation of atrial fibrillation: A systematic review and meta‐analysis.

35. Effect of Carillon Mitral Contour System on patient‐reported outcomes in functional mitral regurgitation: an individual participant data meta‐analysis.

36. Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE‐FMR trial.

38. Representation of women, older patients, ethnic, and racial minorities in trials of atrial fibrillation.

39. Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials.

40. Discontinuation and non‐publication of heart failure randomized controlled trials: a call to publish all trial results.

41. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis.

42. Ferric carboxymaltose for the treatment of iron‐deficient heart failure patients: a systematic review and meta‐analysis.

46. Trends in prevalence of comorbidities in heart failure clinical trials.

47. Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction.

48. Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.

50. Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis.

Catalog

Books, media, physical & digital resources